Unlock AI-driven, actionable R&D insights for your next breakthrough.

Croscarmellose Sodium Hydration Properties: Mechanisms, Quantitative Characterization, And Pharmaceutical Applications

NOV 17, 202666 MINS READ

Want An AI Powered Material Expert?
Here's Patsnap Eureka Materials!
Croscarmellose Sodium Hydration Properties represent a critical functional attribute governing the performance of this internally cross-linked sodium carboxymethylcellulose derivative as a pharmaceutical super-disintegrant. The unique fibrous, cross-linked architecture enables rapid water uptake without gum formation, maintaining particle integrity while achieving moisture absorption capacities exceeding 20% by weight of applied composition 3. Understanding the hydration kinetics, swelling behavior, and structural factors influencing water interaction is essential for formulation scientists optimizing tablet disintegration, moisture management in topical products, and controlled-release systems.
Want to know more material grades? Try Patsnap Eureka Material.

Molecular Structure And Cross-Linking Chemistry Governing Croscarmellose Sodium Hydration

Croscarmellose sodium is synthesized through internal cross-linking of sodium carboxymethylcellulose, achieved by lowering pH during manufacture and applying heat to form carboxylic ester bonds between polymer chains 3. This cross-linking fundamentally alters hydration behavior compared to non-cross-linked carboxymethylcellulose: while the parent polymer forms pasty gums upon moisture exposure with unacceptable cosmetic feel 3, the cross-linked structure maintains fibrous particle integrity during water absorption 3,8,9. The degree of substitution typically ranges from 0.60 to 0.85 for pharmaceutical-grade material 4, with cross-linking density controlled via reaction temperature (40–75°C), pH (2.0–4.0), and duration (0.5–4.0 hours in staged protocols) 4. Patent literature describes synthesis in aqueous organic solvents (water:solvent ratio 1:10) using sulfuric acid catalysis at 15–30% mass fraction, yielding products meeting Chinese Pharmacopoeia and international compendia specifications 1,4.

The fibrous morphology is critical to hydration performance: standard grades exhibit 90% of particles ≤44.5 μm 3, while fine-particle variants achieve median particle size (D50) of 5–36 μm, volume mean diameter (D[4,3]) ≤40 μm, and specific surface area ≥0.3 m²/g 7,8,9. This high surface area-to-volume ratio accelerates initial water contact and wicking, the primary mechanism by which croscarmellose sodium initiates disintegration 8,9. The cross-linked network is water-insoluble yet highly hydrophilic, allowing reversible swelling without dissolution—a property exploited in both rapid-disintegration and sustained-release formulations 11,13.

Quantitative Hydration Capacity And Moisture Absorption Performance

Croscarmellose sodium demonstrates exceptional moisture absorption capacity, with formulations containing 2–20% by weight of the excipient capable of absorbing at least 2.5% moisture based on total applied composition weight, and optimally ≥20% by weight under favorable conditions 3. In body powder applications, compositions with 5–20% croscarmellose sodium provide enhanced moisture absorbency upon topical application, with the material absorbing water many times its own weight without forming pastes 3. Below approximately 2% concentration, water absorbency improvement is markedly limited; above 20%, the tactile sensation shifts undesirably toward that of croscarmellose sodium rather than the powder diluent (talc or starch), and water-swollen particles become visually apparent on moist skin 3. At concentrations exceeding 40%, skin feel and appearance become unacceptable to users 3.

The hydration mechanism involves three synergistic processes:

  • Wicking: Capillary action draws water into the fibrous particle network via surface tension forces, facilitated by the high specific surface area (≥0.3 m²/g for fine-particle grades) 7,8,9.
  • Swelling: Absorbed water causes volumetric expansion of the cross-linked polymer matrix, generating disruptive forces within tablet structures 8,9. Unlike sodium starch glycolate, which can increase disintegration times at high concentrations due to gelling 7,8, croscarmellose sodium maintains disintegration efficiency across a broader concentration range.
  • Deformation Recovery: The fibrous structure exhibits elastic recovery upon hydration, contributing mechanical disruption to compressed dosage forms 8,9.

Moisture-protective storage systems for croscarmellose sodium employ hot-air drying (removing moisture from incoming air) combined with desiccant balls (adsorbing residual moisture in storage cavities), reflecting the material's hygroscopic nature and need for controlled humidity environments to prevent premature hydration 2.

Particle Size Distribution And Its Impact On Hydration Kinetics

Fine-particle croscarmellose sodium grades exhibit significantly altered hydration kinetics compared to standard materials. Patents describe variants with D50 of 5–36 μm (preferably 5 to <25 μm), D[4,3] ≤35 μm, D10 ≤15 μm, and D90 ≤80 μm 7,8,9. The reduction in particle size increases the surface area available for initial water contact, accelerating wicking and swelling onset. For pharmaceutical tablets, this translates to faster disintegration times, particularly beneficial in orally disintegrating tablets (ODTs) and formulations requiring rapid drug release.

However, particle size optimization must balance disintegration speed against flowability and compressibility. Fine particles (<25 μm median) may exhibit reduced bulk density and increased cohesion, necessitating co-processing with flow aids (e.g., colloidal silicon dioxide at 0.5–1% w/w) or direct compression excipients (microcrystalline cellulose at 6–12% w/w) 18. In calcium supplement tablets, for example, 0.5–1% croscarmellose sodium combined with equal amounts of sodium lauryl sulfate (a wetting agent enhancing water penetration) achieves satisfactory disintegration of highly compacted tricalcium phosphate matrices (≥80% w/w) 18.

Hydration Behavior In Pharmaceutical Formulations: Disintegration Versus Controlled Release

Rapid Disintegration Applications

In immediate-release tablets, croscarmellose sodium is typically employed at 2–10% w/w (preferably 5–10%, more specifically 5–7%) to achieve rapid disintegration 5. The hydration-driven swelling generates internal pressures that fracture tablet matrices, with disintegration times often <5 minutes in standard USP dissolution media. For ibandronate sodium tablets, formulations containing 10–15% croscarmellose sodium (combined with microcrystalline cellulose D50 30–150 μm) exhibit stable, rapid dissolution profiles, reducing gastrointestinal side effects by minimizing drug contact time with esophageal mucosa 6. In Kampo extract tablets, croscarmellose sodium paired with sodium hydrogen carbonate (a gas-generating disintegrant) provides synergistic disintegration enhancement, with the hydration-swelling mechanism complementing CO₂ bubble formation 10.

Sustained-Release Formulations

Paradoxically, croscarmellose sodium also functions in extended-release systems when combined with hydrophobic bases (e.g., ethylcellulose) or water-soluble polymers (e.g., hypromellose) and alkaline salts (sodium/potassium carbonate) 11,13. In these formulations (1–30% w/w croscarmellose sodium, preferably 2–25%, optimally 3–20%), initial hydration creates a swollen gel layer that modulates drug diffusion. The presence of magnesium oxide (0.1–30% w/w, preferably 0.5–25%, optimally 1–20%) maintains local alkalinity, slowing erosion of the hydrophilic matrix 11,13. This dual functionality—rapid disintegration at low concentrations in simple matrices versus controlled release in complex multi-component systems—underscores the importance of formulation context in determining hydration outcomes.

Environmental And Processing Factors Affecting Hydration Properties

pH Sensitivity

Croscarmellose sodium hydration is pH-dependent due to ionization of carboxymethyl groups. At acidic pH (1.0–3.0), protonation reduces electrostatic repulsion between polymer chains, decreasing swelling capacity—a principle exploited during synthesis to control cross-linking density 1,4. In physiological pH ranges (6.8–7.4), the material exhibits maximal swelling due to full ionization of carboxylate groups and associated osmotic pressure. Formulations intended for gastric delivery may exhibit slower hydration in the acidic stomach environment (pH 1–3) compared to intestinal conditions (pH 6–7).

Temperature And Humidity

Storage under elevated humidity accelerates premature hydration, necessitating moisture-barrier packaging or desiccant inclusion. Patent CN202210628 describes a moisture-proof storage device employing hot-air circulation (drying incoming air) and desiccant balls within a dual-cavity system, maintaining croscarmellose sodium in a low-moisture state during long-term storage 2. Processing temperatures during tablet compression (typically 20–25°C) are generally insufficient to alter hydration properties, but elevated temperatures during coating or drying steps (70–90°C) may induce minor structural changes if prolonged 4,15.

Solvent Effects During Synthesis

Preparation methods using aqueous ethanol (60% ethanol by mass) for washing and pH adjustment yield products with controlled hydration profiles 4,12,15. The ethanol aqueous solution facilitates removal of unreacted sodium carboxymethylcellulose and by-products (e.g., sodium chloride from HCl neutralization) while minimizing premature swelling of the cross-linked product 12,15. Vacuum drying at 70–90°C post-synthesis ensures residual solvent removal without compromising fibrous structure 4,15.

Applications Beyond Conventional Tablets: Topical, Injectable, And Specialized Delivery Systems

Topical Moisture Management

In body powder formulations, croscarmellose sodium (2–20% w/w, preferably 5–20%) provides superior moisture absorption compared to talc or starch alone, maintaining skin dryness and preventing irritation 3. The fibrous particles absorb perspiration without forming pastes, preserving the powder's free-flowing character and acceptable cosmetic feel. Formulations with 5–8% croscarmellose sodium achieve optimal balance between absorbency and sensory attributes 3.

Injectable Hydrogel Systems

Recent innovations describe micronized croscarmellose sodium in injectable hydrogel compositions for viscosupplementation or dermal filling 14. Heat treatment at 90–150°C (preferably 100–130°C) of water-croscarmellose sodium mixtures produces stable hydrogels without chemical cross-linkers like BDDE (1,4-butanediol diglycidyl ether), addressing safety concerns associated with residual cross-linking agents 14. The hydrogel's swelling capacity provides tissue augmentation, while the cross-linked structure prevents rapid degradation. This application exploits the material's biocompatibility and controlled hydration in physiological environments.

Hygroscopic Matrix Tablets For Moisture-Sensitive APIs

For hydrophobic, water-unstable active pharmaceutical ingredients (e.g., cholesteryl ester transfer protein inhibitors), embedding the drug in a hygroscopic polymer matrix containing croscarmellose sodium (4–8% w/w) protects against moisture-induced degradation while enabling controlled release 5,17. The croscarmellose sodium absorbs environmental moisture, creating a localized hydrated zone that shields the API from bulk water ingress. Combined with hydroxypropylmethyl cellulose (32–41% w/w water-insoluble hygroscopic polymer) and micronized crospovidone, these formulations achieve physical stability over 24+ months at 25°C/60% RH 5,17.

Analytical Characterization Of Croscarmellose Sodium Hydration

Chromatographic Methods

High-performance liquid chromatography with charged aerosol detection (HPLC-CAD) enables quantification of croscarmellose sodium content in complex formulations (e.g., amonavir tablets) without interference from other excipients 16. Sample preparation involves dissolution in mobile phase (typically acetonitrile-water gradients with ion-pairing agents), followed by injection into a reversed-phase column (C18, 4.6 × 250 mm, 5 μm). The universal detection principle of CAD (measuring charged particles post-nebulization) allows accurate quantification regardless of chromophore presence, with recovery rates >95% and RSD <3% 16.

Swelling Index And Water Uptake Measurements

Pharmacopeial methods (e.g., Chinese Pharmacopoeia 2010 edition) specify swelling volume tests: a known mass of croscarmellose sodium is dispersed in water, allowed to hydrate for a defined period (e.g., 10 minutes), and the settled volume measured in a graduated cylinder 1,4. Swelling indices typically range from 4–8 mL/g for pharmaceutical-grade material, with higher values indicating greater hydration capacity. Gravimetric water uptake assays involve equilibrating croscarmellose sodium in controlled humidity chambers (e.g., 75% RH, 25°C) and measuring mass gain over time, yielding moisture sorption isotherms that inform packaging and storage requirements.

Microscopic And Spectroscopic Techniques

Scanning electron microscopy (SEM) reveals the fibrous morphology and surface texture changes upon hydration, with dry particles exhibiting rough, porous surfaces that smooth and swell upon water exposure. Fourier-transform infrared spectroscopy (FTIR) identifies characteristic carboxylate stretching bands (1590–1610 cm⁻¹ for COO⁻) and hydroxyl stretching (3200–3600 cm⁻¹), with peak shifts upon hydration indicating hydrogen bonding between water molecules and polymer chains. Differential scanning calorimetry (DSC) detects bound water (endothermic peak at 80–120°C) versus free water (peak at ~100°C), quantifying hydration states.

Regulatory And Safety Considerations For Hydration-Related Performance

Croscarmellose sodium is generally recognized as safe (GRAS) by the FDA and included in the Inactive Ingredient Database for oral, topical, and injectable routes 14. Acceptable daily intake is not specified due to low systemic absorption and inert nature. However, formulations must control hydration-related quality attributes:

  • Disintegration Time: USP <701> specifies limits (e.g., <30 minutes for uncoated tablets) that depend on croscarmellose sodium hydration kinetics.
  • Dissolution Profile: USP <711> requires ≥80% drug release within specified timeframes, directly influenced by disintegrant hydration and swelling.
  • Moisture Content: Finished products typically maintain <5% moisture (Karl Fischer titration) to prevent premature croscarmellose sodium hydration and loss of disintegration efficiency.

For injectable hydrogels, endotoxin levels (<0.5 EU/mL per USP <85>) and sterility (USP <71>) are critical, with heat sterilization (121°C, 15 minutes) potentially affecting hydration properties and requiring validation 14.

Optimization Strategies For Formulation Scientists

Concentration Tuning

  • Immediate Release: Start with 3–5% w/w croscarmellose sodium; increase to 8–10% if disintegration exceeds targets. Monitor for over-disintegration (tablet friability >1%) indicating excessive swelling forces.
  • Sustained Release: Use 5–15% w/w in combination with rate-controlling polymers (hypromellose 5–20% w/w, ethylcellulose 1–20% w/w) and alkaline salts (sodium carbonate 1–20% w/w) 11,13. Pilot studies should map drug release versus croscarmellose sodium concentration to identify the optimal balance between initial hydration (facilitating matrix formation) and prolonged release.

Particle Size Selection

  • Standard Grades (D50 ~50 μm): Suitable for conventional tablets with moderate disintegration requirements (5–15 minutes).
  • Fine-Particle Grades (D50 15–25 μm): Preferred for ODTs, chewable tablets, and formulations requiring <3-minute disintegration 7,8,9.
  • Micronized Grades (D50 <15 μm): Specialized applications like injectable hydrogels or topical powders where rapid hydration and high surface area are critical 14.

Synergistic Excipient Combinations

  • Wetting Agents: Sodium lauryl sulfate (0.5–1% w/w, equal to croscarmellose sodium concentration) enhances water penetration into hydrophobic matrices 18.
  • Gas-Generating Disintegrants: Sodium bicarbonate (5–15%
OrgApplication ScenariosProduct/ProjectTechnical Outcomes
FMC CORPORATIONOrally disintegrating tablets (ODTs), immediate-release formulations, and pharmaceutical tablets requiring disintegration times <3-5 minutes through enhanced hydration kinetics.Ac-Di-SolFine particle croscarmellose with median particle size 5-36 μm and specific surface area ≥0.3 m²/g enables rapid water wicking and swelling, accelerating tablet disintegration without gelling at high concentrations.
COMBE INCORPORATEDTopical body powders for skin dryness and perspiration control, requiring 5-20% croscarmellose sodium to balance absorbency with acceptable cosmetic feel and appearance.Body Powder FormulationAbsorbs moisture exceeding 20% by weight of applied composition while maintaining fibrous particle integrity without paste formation, providing superior moisture management compared to talc or starch alone.
F. HOFFMANN-LA ROCHE AGMoisture-sensitive pharmaceutical formulations requiring physical stability and controlled drug release, particularly for hydrophobic active ingredients like cholesteryl ester transfer protein inhibitors.CETP Inhibitor TabletHygroscopic matrix containing 4-8% croscarmellose sodium protects hydrophobic water-unstable APIs from moisture-induced degradation while enabling controlled release, achieving 24+ months stability at 25°C/60% RH.
SHIONOGI & CO. LTD.Sustained-release pharmaceutical systems requiring controlled dissolution and resistance to gastrointestinal peristaltic movement, balancing initial hydration-driven matrix formation with prolonged drug release.Extended Release FormulationCombined with alkaline salts (sodium/potassium carbonate 1-20% w/w) and magnesium oxide (0.5-25% w/w), croscarmellose sodium creates swollen gel layer modulating drug diffusion for sustained release over extended periods.
INNATE S.R.L.Viscosupplementation and dermal filling applications requiring injectable hydrogel systems with controlled hydration in physiological environments, avoiding safety concerns of residual cross-linking agents.Injectable HydrogelHeat-treated micronized croscarmellose sodium (90-150°C) produces stable injectable hydrogels without chemical cross-linkers like BDDE, providing tissue augmentation through controlled swelling capacity and biocompatibility.
Reference
  • Sodium croscarmellose and preparation method thereof
    PatentInactiveCN104262649A
    View detail
  • Damp-proof storage device for cross-linked sodium carboxymethyl cellulose
    PatentInactiveCN218663322U
    View detail
  • Body powder composition
    PatentInactiveUS6143285A
    View detail
If you want to get more related content, you can try Eureka.

Discover Patsnap Eureka Materials: AI Agents Built for Materials Research & Innovation

From alloy design and polymer analysis to structure search and synthesis pathways, Patsnap Eureka Materials empowers you to explore, model, and validate material technologies faster than ever—powered by real-time data, expert-level insights, and patent-backed intelligence.

Discover Patsnap Eureka today and turn complex materials research into clear, data-driven innovation!

Group 1912057372 (1).pngFrame 1912060467.png